Unraveling the Complex II Enigma: A New Perspective on Acute Myeloid Leukemia Treatment
Introduction:
In the intricate world of cellular functions, genes interact through interconnected networks, orchestrating the delicate dance of life. Among these networks, a fascinating discovery has emerged, revealing a hidden connection between Complex II and de novo purine biosynthesis in acute myeloid leukemia (AML). This revelation challenges our understanding of metabolic pathways and opens up exciting possibilities for targeted cancer treatment.
The Power of Pathway Mapping:
Scientists have developed a groundbreaking tool, pathway coessentiality mapping, to unravel the complex relationships between gene pathways. By analyzing patterns of essentiality across various conditions, this approach has successfully identified critical gene pairs. However, scaling this method to genome-wide analysis presented a daunting challenge, with nearly 200 million possible interactions. Enter pathway-level mapping, a novel strategy that organizes coessentiality data into higher levels, revealing associations that single gene-gene queries might miss.
Unveiling Complex II's Unique Associations:
The electron transport chain (ETC) served as the perfect test case for this innovative approach. Its protein complexes, working in harmony, facilitate electron transport and hydrogen pumping, supporting vital biosynthetic functions. By examining the connections between ETC complexes and cellular pathways, researchers discovered a surprising pattern. While complexes III and IV showed strong similarity in their pathway connections, and complexes I, III, IV, and V formed a tight cluster, Complex II stood apart, displaying a unique pathway signature.
The Link to Purine Synthesis:
Computational analysis revealed Complex II's unexpected role in regulating purine synthesis, a critical process for cancer cell metabolism. This discovery led researchers to investigate further, uncovering a direct link between Complex II and purine nucleotides. To validate this connection, they performed loss-of-function CRISPR screening, confirming that nucleotide biosynthesis enzymes play a crucial role in AML cells' sensitivity to Complex II inhibition.
Targeting Complex II in AML:
Chemical screening revealed that AML and other hematological malignancies are particularly sensitive to Complex II inhibition. This finding was further supported by data from the Cancer Dependency Map, which showed that blood cancers have greater sensitivity to Complex II disruption. To test this requirement in a physiological context, researchers used a syngeneic MLL-AF9-driven mouse model of AML, successfully demonstrating Complex II's essential role in AML survival both in vitro and in vivo.
Unraveling the Metabolic Circuit:
To understand how Complex II influences purine metabolism, researchers performed stable-isotope tracing with labeled glucose or glutamine. They discovered that Complex II inhibition caused a metabolic bottleneck, blocking carbon flow through the tricarboxylic acid (TCA) cycle while disrupting glutamine's critical nitrogen donation to purine synthesis. This disruption led to the accumulation of glutamate, which, in turn, suppressed purine synthesis and enhanced cell death.
Glu's Impact on the AML Proteome:
Isothermal proteome profiling revealed that glutamate broadly impacts the AML proteome, affecting protein dynamics and metabolism. This finding suggests that glutamate accumulation may directly impact purine biosynthesis and drive other pleiotropic effects. The study identified over 5,000 proteins in AML lysates, including those involved in translation and proteasome function, which were enriched with high confidence in glutamate-interacting proteins.
Complex II as a High-Risk Molecular Feature:
Survival analysis of The Cancer Genome Atlas (TCGA) data revealed that high expression of Complex II subunits SDHA and SDHB was associated with the poorest survival for individuals with AML. This finding prompted researchers to investigate Complex II's role in human AML, leading to the discovery of its unique role as a high-risk molecular feature.
Discussion and Future Directions:
The study's innovative algorithm, which goes beyond established gene-gene coessentiality mapping, has revealed complex interactions across biological pathways. By applying this approach to examine relationships among ETC protein complexes, researchers discovered a new association between Complex II and purine synthesis. This finding not only adds to the growing body of work linking the ETC and TCA cycle to non-canonical functions but also highlights the potential for Complex II to be used therapeutically against cancer. Further studies are needed to explore the specific mechanisms by which glutamate exerts its effects and to determine whether the essential functions of Complex II are shared among subsets of cancers.
